These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28356484)

  • 1. A randomized placebo-controlled clinical study of
    Wu Y; Feng J; Hu W; Luo Q
    Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28356484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer.
    Liu Z; Wei Z; Hu Y; Gao F; Hao L; Fang P; Sun S; Li J; Jiao S
    Med Oncol; 2015 Aug; 32(8):216. PubMed ID: 26168982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.
    Gong W; Sun P; Mu Z; Liu J; Yu C; Liu A
    Anticancer Res; 2017 Aug; 37(8):4687-4691. PubMed ID: 28739772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma.
    Jin F; Zhu H; Shi F; Kong L; Yu J
    Clin Interv Aging; 2016; 11():167-73. PubMed ID: 26929611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: A retrospective study.
    Liu Y; Dong Y; Zhu H; Jing W; Guo H; Yu J
    Cancer Med; 2020 Feb; 9(4):1365-1373. PubMed ID: 31876976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
    Morgensztern D; Cobo M; Ponce Aix S; Postmus PE; Lewanski CR; Bennouna J; Fischer JR; Juan-Vidal O; Stewart DJ; Fasola G; Ardizzoni A; Bhore R; Wolfsteiner M; Talbot DC; Jin Ong T; Govindan R; On Behalf Of The Abound L Investigators
    Cancer; 2018 Dec; 124(24):4667-4675. PubMed ID: 30383906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
    Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
    J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301.
    Sakata S; Saeki S; Okamoto I; Otsubo K; Komiya K; Morinaga R; Yoneshima Y; Koga Y; Enokizu A; Kishi H; Hirosako S; Yamaguchi E; Aragane N; Fujii S; Harada T; Iwama E; Semba H; Nakanishi Y; Kohrogi H
    Lung Cancer; 2016 Sep; 99():41-5. PubMed ID: 27565912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes.
    Hirsh V; Ko A; Pilot R; Renschler MF; Socinski MA
    Clin Lung Cancer; 2016 Sep; 17(5):367-374. PubMed ID: 27230605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
    Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G
    J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
    Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
    J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment.
    Langer CJ; Hirsh V; Ko A; Renschler MF; Socinski MA
    Clin Lung Cancer; 2015 Mar; 16(2):112-20. PubMed ID: 25572008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.
    Weiss JM; Pennell N; Deal AM; Morgensztern D; Bradford DS; Crane J; West HJ; Lee C; Pecot C; Stevenson JP; Irvin W; Socinski M; Stinchcombe T; Villaruz LC; Muss HB
    Cancer; 2020 Mar; 126(5):1060-1067. PubMed ID: 31943168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer.
    Kato Y; Okuma Y; Watanabe K; Yomota M; Kawai S; Hosomi Y; Okamura T
    Cancer Chemother Pharmacol; 2019 Aug; 84(2):351-358. PubMed ID: 30993397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study.
    Dechow T; Riera-Knorrenschild J; Hackanson B; Janssen J; Schulz H; Chiabudini M; Fischer von Weikersthal L; Budweiser S; Nacke A; Taeuscher D; Welslau M; Potthoff K
    Cancer Med; 2021 Nov; 10(22):8127-8137. PubMed ID: 34668662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent.
    Saxena A; Schneider BJ; Christos PJ; Audibert LF; Cagney JM; Scheff RJ
    Med Oncol; 2016 Feb; 33(2):13. PubMed ID: 26749586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non-Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/Carboplatin.
    Hirsh V; Wan Y; Lin FJ; Margunato-Debay S; Ong TJ; Botteman M; Langer C
    Clin Lung Cancer; 2018 Sep; 19(5):401-409.e4. PubMed ID: 29903552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II clinical study of using nab-paclitaxel as second-line chemotherapy for Chinese patients with advanced non-small cell lung cancer.
    Hu W; Zhang Z
    Med Oncol; 2015 Jun; 32(6):498. PubMed ID: 25944796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the clinical outcome of nab-paclitaxel in Chinese patients with advanced non-small-cell lung cancer.
    Zeng J; Yin J; Yuan D; Yang W; Liang W; Wu G; Song Y
    Clin Respir J; 2017 Sep; 11(5):632-639. PubMed ID: 26404101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II Study of the Modified Weekly Nab-paclitaxel Regimen in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer.
    Yoshimura N; Sawa K; Nakai T; Matsumoto Y; Mitsuoka S; Kimura T; Asai K; Yana T; Kawaguchi T; Hirata K
    Am J Clin Oncol; 2021 Dec; 44(12):613-618. PubMed ID: 34753884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.